Hilary Levy is Director & co-founder of MBI Pharma. Hilary has over 21 years pharmaceutical experience in various commercial roles both in Israel and worldwide. Hilary has been with the Mawdsleys Group in a Senior International role for the last 10 years, and prior to that was instrumental to the formation and success of the local Eli Lilly affiliate in Israel as its Commercial Manager. Hilary obtained her BSc from University of Manchester Institute of Science & Technology (UMIST).
Ofer Yaakobi is CEO and co-founder of MBI Pharma. During his 16 year experience in the pharmaceutical industry, for 7 years, worked at the Clalit HMO, biggest Sick Fund in Israel and was responsible for the Special Projects Unit within the Purchasing Department, managing all unlicensed medicines, nuclear medicine and raw materials. Before that, Ofer Yaakobi was QA Manager at Clalit with responsibility for North Israel. Previously, he was QA responsible at Teva Pharmaceuticals in the Chemical Division, managing several FDA, EMA and private customer audits. Ofer obtained his Pharmacist Degree from the Hebrew University in Jerusalem and his MBA Degree with marketing specialization from the Bar-Ilan University in Tel Aviv.
Dr Alain Zeitoun is responsible for Business Development & Medical at MBI Pharma and at the Mawdsleys Group International since 2015. During his extensive industry experience, Alain Zeitoun has successfully held positions as Business Unit Director and European Marketing Leader at Merck Sharp and Dohme (MSD) in Israel and in Europe, as well as Senior Medical and Marketing positions at P&G Pharma and Boehringer Ingelheim in France. Beyond pharma, Alain Zeitoun has also been CEO of an Israeli medical device startup. Alain obtained his M.D. Degree from Paris Medical School, and his Business Master Degree from ESCP Europe Business School, Paris.